Bio-Techne Corp
TECH: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$18.00 | Mvtbzjw | Fmnfgtrgl |
Bio-Techne Starts Fiscal 2022 With Strong Growth Offset by Labor-Related Margin Pressure
Narrow-moat Bio-Techne had a strong start to fiscal 2022, reporting organic sales growth of 21% and adjusted EPS increasing to $1.83 from $1.43 last year. We are maintaining our $320 fair value estimate and are not materially changing our long-term expectations. The shares trade well above our fair value estimate--at a 55% premium--even following the 4% decline in Nov. 2 trading.